Impact of Computerized Decision Support for ANTIBIOtic Prescription in Cancer Patients With Febrile NEutropenia in the Emergency Department on Treatment Failure. (ANTIBIONEED)
Impact of Computerized Decision Support for ANTIBIOtic Prescription in Cancer Patients With Febrile NEutropenia in the Emergency Department on Treatment Failure. A Randomized Cluster-controlled Trial.
Treatment of patients with febrile neutropenia (FN) attending Emergency Departments (EDs) relies on rapid antibiotic initiation in order to control a presumed infection. The choice of initial antibiotics is empirical and depends on patient's prior colonization or infection by multi-drug resistant pathogens (MDRPs) and risk stratification. Stratification of high-risk patients needing broad-spectrum antibiotics is debated. Thus, for non-specialist physicians, this choice may be challenging, leading to inappropriate initial antimicrobial regimens, potential risks for the patient and higher costs. Furthermore, international guidelines recommended to develop antibiotic stewardship programs and promoted an initial strategy based on escalation or de-escalation approaches, with early reassessment depending on patients' clinical course and microbiological results. Nevertheless, this interesting strategy may increase the level of complexity for the choice of the initial antibiotic regimen by non-specialist emergency physicians who are often the first prescribers in this context.
We developed an interactive computerized decision support app (CDSA) for initial antibiotic prescription and early revaluation in patients with FN. The first goal of this app is to assist non-specialized physicians in choosing initial antimicrobial regimen for patients with FN when they attend EDs. It uses an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the app is also designed to propose an algorithm of antibiotic revaluation at day 3-4 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
We hypothesize that such a CDSA may improve the adherence to guidelines for the choice of initial antibiotic regimen for FN in the ED, favour early antibiotic reassessment for hospitalized patients, both decreasing the risk of treatment failure.
研究概览
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Olivier Peyrony
- 电话号码:+33142494804
- 邮箱:olivier.peyrony@aphp.fr
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- age ≥ 18 years;
- reported or observed fever at arrival at the ED (≥38.3° C on one occasion or ≥38°C on two or more occasions within 1 h);
- chemotherapy-induced neutropenia (absolute neutrophil count ≤500/mm3 or ≤1000/mm3 and anticipated to decrease to fewer than 500/mm3 within 24 to 48 h).
Exclusion Criteria:
- refusal to participate;
- prior inclusion in the study for a previous episode of FN;
- any intravenous antibiotic administration during the preceding 72 h;
- renal failure requiring renal replacement therapy or with an estimated creatinine clearance of less than 20 ml/min;
- palliative status with life expectancy of less than three days;
- pregnancy, absence of health insurance, mental deficiency or inability to understand informed consent, no French speaking;
- patient with a microbiological documented infection when arriving at the ED (e.g. positive blood culture).
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
其他:Control Group
As routine care, the choice of the initial antibiotic regimen will be let to the discretion of the emergency physician.
|
The choice of the initial antibiotic regimen will be let to the discretion of the emergency physician
|
实验性的:computerized decision support app (CDSA) Group
|
Implementation of an Computerized Decision support app (CDSA) : physician will use this app to help him in the antibiotic choice.
This app is an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics.
Secondly, the application is also designed to propose an algorithm of antibiotic revaluation at day 3 for hospitalized patients, depending on patient clinical course, and biological and microbiological results.
The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Treatment failure
大体时间:7 days following inclusion
|
Treatment failure will be defined by any escalation of the assigned empirical initial antibiotic treatment (e.g. adjunction of aminoglycoside, glycopeptide or other anti-gram positive or any broadening of the beta-lactam spectrum) during the 7 days following inclusion, in relation with at least one of the following reasons:
|
7 days following inclusion
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of initial antibiotic regimen adhering to the international guidelines
大体时间:at inclusion
|
at inclusion
|
|
Time to antibiotic initiation from patient triage at the emergency department (minutes)
大体时间:at inclusion
|
at inclusion
|
|
Number of revaluations of initial antibiotic regimen at day 3 depending on patient clinical course and microbiological results;
大体时间:at 3 days
|
at 3 days
|
|
Number of antimicrobial spectrum reductions
大体时间:at 3 days
|
at 3 days
|
|
Number of antibiotic regimens with carbapenems, aminoglycosides or glycopeptides
大体时间:at inclusion
|
at inclusion
|
|
Number of days of Carbapenems, aminoglycosides and glycopeptides therapy
大体时间:up to 3 months
|
up to 3 months
|
|
Number of super-infections
大体时间:up to 3 months
|
A super-infection will be defined as new, persistent or worsening symptoms and/or signs of infection associated with the isolation of a new pathogen (different, or different susceptibilities) or the development of a new site of infection;
|
up to 3 months
|
Number of super-infections due to clostridium difficile
大体时间:up to 3 months
|
up to 3 months
|
|
Number of colonization
大体时间:up to 3 months
|
Colonization will be defined as isolation during or after therapy of Gram-negative bacteria resistant to the beta-lactam included in the empirical regimen, without symptoms or signs of infection
|
up to 3 months
|
Number of episodes of nephrotoxicity
大体时间:up to 3 months
|
up to 3 months
|
|
Number of episodes of other toxicities
大体时间:up to 3 months
|
Toxicities will be defined according to the common terminology criteria for adverse events
|
up to 3 months
|
Occurrence of any complication during hospital stay or follow-up
大体时间:up to 3 months
|
up to 3 months
|
|
Number of re-hospitalizations due to a complication related to the initial infection
大体时间:within 7 days of discharge
|
within 7 days of discharge
|
|
Antibiotic treatment duration
大体时间:up to 3 months
|
up to 3 months
|
|
Length of hospital stay
大体时间:up to 3 months
|
up to 3 months
|
|
Total 3-month costs
大体时间:at 3 months
|
at 3 months
|
|
Number of deaths related to infection
大体时间:at 3 months
|
Death related to infections will be defined according to the physician in charge of the patient
|
at 3 months
|
Number of in-hospital death
大体时间:up to 3 months
|
up to 3 months
|
|
Survival status
大体时间:at day 90
|
at day 90
|
|
Health related quality of life
大体时间:at inclusion
|
Quality of life will be assessed using the EQ5D5L scale.
The EQ5D5L scale is composed of two parts: a descriptive system and the EQ Visual Analog Scale (EQ VAS).
The descriptive system has five dimensions.
Each dimension has five levels: no problems, mild problems, moderate problems, severe problems and extreme problems.
The descriptive system ranges from 1 to 25, the higher the score the worse the quality of life.
The score goes from VAS 0 to 100, the higher the VAS score the better the quality of life.
|
at inclusion
|
Health related quality of life.
大体时间:at day 30
|
Quality of life will be assessed using the EQ5D5L scale.
The EQ5D5L scale is composed of two parts: a descriptive system and the EQ Visual Analog Scale (EQ VAS).
The descriptive system has five dimensions.
Each dimension has five levels: no problems, mild problems, moderate problems, severe problems and extreme problems.
The descriptive system ranges from 1 to 25, the higher the score the worse the quality of life.
The score goes from VAS 0 to 100, the higher the VAS score the better the quality of life.
|
at day 30
|
Health related quality of life.
大体时间:at 3 months
|
Quality of life will be assessed using the EQ5D5L scale.
The EQ5D5L scale is composed of two parts: a descriptive system and the EQ Visual Analog Scale (EQ VAS).
The descriptive system has five dimensions.
Each dimension has five levels: no problems, mild problems, moderate problems, severe problems and extreme problems.
The descriptive system ranges from 1 to 25, the higher the score the worse the quality of life.
The score goes from VAS 0 to 100, the higher the VAS score the better the quality of life.
|
at 3 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
routine care的临床试验
-
Copenhagen University Hospital at HerlevRigshospitalet, Denmark未知
-
University Health Network, Toronto招聘中淋巴瘤 | 淋巴增生性疾病 | 乳腺癌一期 | 乳腺癌二期 | 结直肠癌 II 期 | 结直肠癌 III 期 | 乳腺癌三期 | 结直肠癌 I 期 | 头颈癌 III 期 | 乳腺癌,0 期 | 头颈癌 I 期 | 头颈癌 II 期加拿大
-
Emory UniversityFoundation for Physical Therapy, Inc.完全的
-
Fondation Oeuvre de la Croix Saint-Simon撤销
-
VA Office of Research and Development完全的